Denali Therapeutics, Inc. (DNLI)
17.54
-2.12
(-10.76%)
USD |
NASDAQ |
Dec 10, 16:00
17.54
0.00 (0.00%)
After-Hours: 20:00
Denali Therapeutics Cash from Investing (Quarterly): 57.83M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Masimo Corp. | 282.30M |
| Novavax, Inc. | -136.53M |
| iRhythm Technologies, Inc. | -89.20M |
| AIM ImmunoTech, Inc. | 0.296M |
| Protalix Biotherapeutics, Inc. | -0.504M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -107.30M |
| Cash from Financing (Quarterly) | -0.778M |
| Free Cash Flow | -410.85M |
| Free Cash Flow Per Share (Quarterly) | -0.6143 |
| Free Cash Flow to Equity (Quarterly) | -103.76M |
| Free Cash Flow to Firm (Quarterly) | -105.92M |
| Free Cash Flow Yield | -13.67% |